Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Northwell Health Physicians Partners Radiation Medicine at Queens — Forest Hills, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in New York: - Albany Medical Center — Albany, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in New York: - Associated Medical Professionals - Urology ( Site 0081) — Syracuse, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in New York: - NYU Langone Hospitals — Brooklyn, New York
- NYU Langone Hospital Long Island — Mineola, New York
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center — New York, New York
- Columbia University Medical Center — New York, New York
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in New York: - Montefiore Medical Center - Medical Park — The Bronx, New York
- Montefiore Medical Center — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in New York: - Mount Sinai Hosp Med School — New York, New York
- Associated Med Professionals of NY — Syracuse, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in New York: - Albany Medical College, Department of Urology — Albany, New York
- Mount Sinai Doctors Urology Faculty Practice — New York, New York
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in New York: - NYOH Albany Cancer Center — Albany, New York
- White Plains Hospital — White Plains, New York
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in New York: - VA NY Harbor Healthcare System, New York, NY — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in New York: - Columbia University Herbert Irving Comphrensive Cancer Center — New York, New York
Phase 3 Recruiting Academic/Other
The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researcher…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06986083
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Consent only) — Commack, New York
- Memorial Sloan Kettering Westchester (Consent Only) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Consent Only) — Uniondale, New York
Phase 3 Recruiting Academic/Other
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Academic/Other
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…
Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Sites in New York: - Roswell Park Comprehensive Cancer Center — Buffalo, New York
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in New York: - Garnet Health Medical Center — Middletown, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in New York: - Research Site 107 — New York, New York
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in New York: - NYU Langone Health Perlmutter Cancer Center — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University - The Trustees of Columbia University in the City of New York — New York, New York
- Montefiore Medical Center — New York, New York
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester — Rochester, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- Memorial Sloan Kettering Cancer Center - NYC — New York, New York
- Weill Medical College of Cornell University — New York, New York
- University of Rochester Medical Center, James P. Wilmot Cancer Center — Rochester, New York
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in New York: - Research Site — Commack, New York
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in New York: - Memorial Sloan Kettering Cancer Center — Long Island City, New York
- Associated Medical Professionals — Syracuse, New York
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in New York: - Roswell Park Cancer Institute IDS — Buffalo, New York
- Memorial Sloan Kettering Hospital — New York, New York